Sort   by:  
 Page size 
TranscriptomicsSpectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma
Multiple BRAF inhibitor resistance mechanisms have been described, however their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. Excised progressing BRAFV600 mutant melanoma metastases (Prog) from patients treated...
ORGANISM(S): Homo sapiens 
2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress
TranscriptomicsPredominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma.
One third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within six months. Treatment options for these patients remain limited. Here we analyse twenty BRAFV600 mutant melanoma metastases derived from 10 patients treated with the combination of deb...
ORGANISM(S): Homo sapiens 
2014-12-03 | E-GEOD-61992 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human Melanoma cell lines to investigate differences in wild-type p14ARF and mutant 14ARF
35 Melanoma cell lines hybridized to Affymetrix Hu133_Plus 2 microarrays were analysed for genes differentially expressed between cell lines carrying wild-type p14ARF and those with mutant 14ARF. All of these cell lines contained wild-type p53 (so that the effects of p14ARF mutations could be analys...
ORGANISM(S): Homo sapiens 
2008-06-15 | E-GEOD-7152 | biostudies-arrayexpress
Sort   by:  
 Page size